AGAP2-AS1 serves as an oncogenic lncRNA and prognostic biomarker in glioblastoma multiforme.
Long noncoding RNA (lncRNA) AGAP2 antisense RNA 1 (AGAP2-AS1) has been suggested to function as an oncogenic lncRNA in lung cancer, breast cancer, and anaplastic glioma. However, the expression pattern and molecular mechanism of AGAP2-AS1 in glioblastoma multiforme (GBM) remains unknown. The purpose of this study is to present more evidence about the clinical and biological function of AGAP2-AS1 in GBM. In our results, we found AGAP2-AS1 expression was increased in GBM compared with adjacent normal brain tissues or low-grade glioma tissues, and there was no significantly different between low-grade glioma tissues and normal tissues. Kaplan-Meier survival analysis indicated patients with GBM having high-expression of AGAP2-AS1 had shorter overall survival time than those with low expression of AGAP2-AS1. The loss-of-function studies showed that downregulation of AGAP2-AS1 depressed cell proliferation, migration, and invasion, and promoted cell apoptosis in GBM. In summary, AGAP2-AS1 is a prognostic biomarker for patients with GBM, and functions as an oncogenic lncRNA to modulate GBM cell proliferation, apoptosis, migration, and invasion, which suggests that AGAP2-AS1 is potential therapeutic target for GBM.
['Tian|Yanlong|Y|', 'Zheng|Yong|Y|', 'Dong|Xin|X|0000-0001-5701-8584']
D017209:Apoptosis D014408:Biomarkers, Tumor D045744:Cell Line, Tumor D005909:Glioblastoma D005910:Glioma D006801:Humans D066298:In Vitro Techniques D011379:Prognosis D062085:RNA, Long Noncoding D060888:Real-Time Polymerase Chain Reaction
AGAP2-AS1 lncRNA glioblastoma multiforme glioma GBM